The Effects of Lifebloom One on Physical Activity After Acquired Brain Injury

Last updated: March 6, 2025
Sponsor: Lifebloom
Overall Status: Completed

Phase

N/A

Condition

Stroke

Neurologic Disorders

Cerebral Ischemia

Treatment

Lifebloom One

Clinical Study ID

NCT05977270
2021-A00072-39
  • Ages > 18
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate the effects of Lifebloom One in people who have suffered a stroke or a traumatic brain injury.

The main questions to be answered are:

  • Does Lifebloom One allow users to spend more time standing each day?

  • Does Lifebloom One allow users to improve their balance and gait?

Participants will use Lifebloom One during 8 weeks.

For each participant, gait and balance are compared either with and without Oxilio or before and after Lifebloom One intervention.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Stroke or traumatic brain injury more than 2 months old

  • Unable to walk without assistance

  • Expected length of stay equal to or greater than 4 months

Exclusion

Exclusion Criteria:

  • Anthropometric incompatibility with Oxilio

  • Unable to walk prior to brain injury

  • No functional upper limb

  • Complete sensory deficit in the lower limb(s)

  • Degenerative impairment (tumor, neurodegenerative disease, etc.)

Study Design

Total Participants: 5
Treatment Group(s): 1
Primary Treatment: Lifebloom One
Phase:
Study Start date:
September 15, 2023
Estimated Completion Date:
August 29, 2024

Connect with a study center

  • Physical Medicine and Rehabilitation Department - Pitié-Salpêtrière Hospital

    Paris, 75013
    France

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.